Morgan Stanley
RANI icon

Morgan Stanley’s Rani Therapeutics RANI Stock Holding History

Morgan Stanley’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.9K Sell
24,370
-4,307
-15% -$5.5K ﹤0.01% 6772
2025
Q4 		$38.7K Buy
28,677
+21,927
+325% +$33.1K ﹤0.01% 6507
2025
Q3 		$3.37K Sell
6,750
-270
-4% -$141 ﹤0.01% 7185
2025
Q2 		$3.61K Sell
7,020
-7,566
-52% -$6.17K ﹤0.01% 7114
2025
Q1 		$18.4K Buy
14,586
+8,085
+124% +$12K ﹤0.01% 6600
2024
Q4 		$8.91K Buy
6,501
+1,250
+24% +$2.63K ﹤0.01% 6847
2024
Q3 		$11.3K Buy
5,251
+2,300
+78% +$6.59K ﹤0.01% 6682
2024
Q2 		$11.2K Buy
2,951
+500
+20% +$2.59K ﹤0.01% 6636
2024
Q1 		$7.62K Sell
2,451
-7,951
-76% -$27.3K ﹤0.01% 6790
2023
Q4 		$34.5K Buy
10,402
+9,502
+1,056% +$22K ﹤0.01% 6478
2023
Q3 		$1.96K Sell
900
-1,010
-53% -$3.86K ﹤0.01% 7135
2023
Q2 		$7.87K Buy
1,910
+1,380
+260% +$6.41K ﹤0.01% 6890
2023
Q1 		$2.73K Sell
530
-1,640
-76% -$9.86K ﹤0.01% 7183
2022
Q4 		$12.8K Sell
2,170
-2,544
-54% -$18.6K ﹤0.01% 6847
2022
Q3 		$45K Buy
4,714
+616
+15% +$6.53K ﹤0.01% 6457
2022
Q2 		$43K Buy
4,098
+820
+25% +$9.41K ﹤0.01% 6679
2022
Q1 		$44K Sell
3,278
-495
-13% -$8.21K ﹤0.01% 6768
2021
Q4 		$61K Buy
+3,773
New +$85.7K ﹤0.01% 6718

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Morgan Stanley's RANI Position: Q1 2026 in Review

Morgan Stanley reduced its Rani Therapeutics (RANI) stake by 15% in Q1 2026, selling an estimated $5.5K and leaving 24,370 shares worth $17.9K. The position accounts for ﹤0.01% of the portfolio, ranked #6772.

Morgan Stanley first reported a position in RANI in Q4 2021 and has held it in 18 quarters since. The position peaked at $61K in Q4 2021. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Morgan Stanley held 24,370 shares of Rani Therapeutics worth $17.9K as of Q1 2026.
  • Morgan Stanley sold 4,307 Rani Therapeutics shares in Q1 2026, an estimated $5.5K.
  • Rani Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6772 holding.
  • Morgan Stanley first reported a position in Rani Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • Morgan Stanley's Rani Therapeutics position peaked at $61K in Q4 2021.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.